Novavax to supply 40M doses of COVID-19 vaccine to South Korea

Fundamentals Novavax

For this year the company, located in Gaithersburg revenue will be around 543.9 million USD. This is according to the average of the analysts' estimates. This is quite more than 2019's revenue of 18.66 million USD.

Historical revenues and results Novavax Inc plus estimates 2020

The analysts expect for 2020 a net loss of 304 million USD. According to most of the analysts the company will have a loss per share for this book year of 5.29 USD. So the price/earnings-ratio equals -51.79.

For this year analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies equals a moderate 0.11 percent.

Novavax Inc 's market capitalization is around 5.27 billion USD. The Novavax Inc stock was the past 12 months quite unstable. Since last February the stock is even 3346 percent higher. This year the stock price moved between 7 and 332 dollar.

Historical stock prices Novavax Inc

Click here for dividend Novavax Inc. At 20.53 the stock trades 2.46 percent lower at 273.98 USD.

Analist.nl Nieuwsdienst: +31 084-0032-842
nieuws@analist.nl

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.